MDRX Veradigm
- 7.900
- +0.220+2.86%
Veradigm News
Deutsche Bank Downgrades Veradigm to Hold From Buy, Adjusts Price Target to $10 From $15
Veradigm Analyst Ratings
Veradigm's Challenging Outlook: Hold Rating Justified Amid Revenue Growth, Margin Pressures, and Audit Concerns
Analysts Conflicted on These Healthcare Names: Veradigm (OtherMDRX), ADC Therapeutics (ADCT) and Sangamo Biosciences (SGMO)
Veradigm Analyst Ratings
RBC Halves Price Target on Veradigm to $11 From $22, Keeps Outperform Rating
Barclays Starts Allscripts Healthcare Solutions With Equalweight Rating, $11 Price Target
Barclays Initiates Coverage On Veradigm With Equal-Weight Rating, Announces Price Target of $11
Veradigm Analyst Ratings
Deutsche Bank Adjusts Veradigm Price Target to $15 From $18, Maintains Buy Rating
Stephens & Co. Reiterates Equal-Weight on Veradigm, Maintains $13 Price Target
Veradigm Analyst Ratings
Stephens & Co. Reiterates Equal-Weight on Veradigm, Maintains $13 Price Target
Veradigm Analyst Ratings
Research Alert: CFRA Drops Analytical Coverage Of Veradigm Inc.
RBC Capital Reaffirms Their Buy Rating on Veradigm (MDRX)
Stephens Initiates Allscripts Healthcare Solutions at Equalweight With $13 Price Target
Stephens & Co. Initiates Coverage On Veradigm With Equal-Weight Rating, Announces Price Target of $13
Piper Sandler Downgrades Veradigm to Neutral, Raises Price Target to $18.5
Argus Research Upgrades Allscripts Healthcare to Buy, Announces $26 Price Target
Analysis
Price Target
No Data
